国泰海通|2025上海先导产业大会暨第14届医药CEO论坛+第5届人工智能大会
国泰海通证券研究·2025-08-30 09:02

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries Forum and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion in the pharmaceutical industry, as well as the integration of artificial intelligence in various sectors [1][4]. Summary by Sections Pharmaceutical Main Venue - September 4 Morning - The forum will feature a series of roundtable discussions and keynote speeches, including topics such as the global expansion of Chinese pharmaceutical companies and the search for the next blockbuster drug [4]. - Key discussions will include the future of drug development, focusing on next-generation weight loss drugs and the competitive landscape of Chinese pipelines [4][5]. Pharmaceutical Main Venue - September 4 Afternoon - Afternoon sessions will cover the potential of pharmaceutical assets in various disease and technology fields, as well as the commercialization challenges faced by innovative drugs in a global competitive environment [4][6]. - Discussions will also explore advancements in drug development platforms and the implications of brain-machine interfaces [6]. TMT Sub-Forum - September 4 Afternoon - The TMT sub-forum will address the impact of AI on various industries, including gaming, e-commerce, and video innovation [7][8]. - Key topics will include the evolution of AI applications and their potential to reshape the mobile internet ecosystem [8]. Pharmaceutical Sub-Forum - September 5 Afternoon - The pharmaceutical sub-forum will focus on ADC technology, probiotic delivery systems, and the future of dual antibodies and XDC development [9]. - Discussions will also cover the integration of medical insurance and the innovation of multi-level medical security systems in China [9]. Participating Companies - A diverse range of companies from the pharmaceutical, medical device, and technology sectors are expected to participate, including major players like Hengrui Medicine, Innovent Biologics, and Mindray Medical [12][14].